NDA 021773 · Astrazeneca Ab
Byetta
Exenatide Synthetic · Subcutaneous · GLP-1 Receptor Agonist
NovelDiscontinuedLast checked: Nov 19, 2026Latest source record: Sep 2, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Apr 28, 2005
Approved uses
6
Original approval plus efficacy supplements
Registered trials
302
90 Phase 3, 8 recruiting
FAERS reports
52,320
14,635 serious, 1,764 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 2, 2025.
BYETTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • BYETTA contains exenatide. Coadministration with other exenatide-containing products is not recommended. BYETTA (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 , 14 ) Limitations of Use • Coadministration with other exenatide-containing products is not recommended ( 1 ).
Mechanism: Incretins, such as glucagon-like peptide-1 (GLP-1), enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. BYETTA is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. The amino acid sequence of exenatide partially overlaps that of human GLP-1. Exenatide has been shown to bind and activate the human GLP-1 receptor in vitro . This leads to an increase in both...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 4, 2021 Supplement 45 · Efficacy LabelLetter
- Nov 24, 2014 Supplement 36 · Efficacy LetterLabel
- Oct 19, 2011 Supplement 30 · Efficacy LabelLetter
- Oct 19, 2011 Supplement 29 · Efficacy LetterLabel
- Dec 22, 2006 Supplement 2 · Efficacy LetterLabel
- Apr 28, 2005 Original approval · Type 1 - New Molecular Entity NovelLabelReviewOther Important Information from FDA
2 products under this application
- BYETTA · EXENATIDE SYNTHETIC 300MCG/1.2ML (250MCG/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued · TE AP
- BYETTA · EXENATIDE SYNTHETIC 600MCG/2.4ML (250MCG/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Exenatide Synthetic" as an intervention, any sponsor and status, largest first.
- Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes MellitusPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01144338 · 14,752 participants · Start Jun 18, 2010 · Primary completion Apr 21, 2017
Drug: Exenatide Once Weekly; Placebo · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Glendale, Arizona; Phoenix, Arizona · 629 sites in all
- A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650Pivotal-lookingCompleted
Intarcia TherapeuticsIndustry
NCT01455896 · 4,156 participants · Start Mar 2013 · Primary completion Mar 2016
Drug: ITCA 650 · For: Type 2 Diabetes
Sites: Chandler, Arizona; Hayward, California; Long Beach, California · 42 sites in all
- Autoinjector Device Assessment StudyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02349802 · 3,052 participants · Start Feb 2013 · Primary completion Dec 2013
Drug: Auto-injector with exenatide suspension; Syringe with exenatide suspension · For: Healthy Subjects
Sites: Tempe, Arizona; Lincoln, Nebraska
- GLP-1 and Hyperoxia for Organ Protection in Heart SurgeryPivotal-lookingStatus unknown
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT02673931 · 1,400 participants · Start Feb 2016 · Primary completion Sep 2024
Drug: Byetta (Lilly, Exenatide); Conoxia (AGA, oxygen) and 1 more · For: Coronary Disease; Shock, Cardiogenic; Renal Failure and 3 more
Sites: Copenhagen, Denmark
- A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00717457 · 1,189 participants · Start Jul 2008 · Primary completion Mar 2011
Drug: exenatide; taspoglutide and 1 more · For: Diabetes Mellitus Type 2
Sites: Haleyville, Alabama; Mobile, Alabama; Montgomery, Alabama · 216 sites in all
- A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 DiabetesPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00960661 · 1,036 participants · Start Sep 2009 · Primary completion Aug 2012
Drug: exenatide; insulin lispro and 2 more · For: Type 2 Diabetes Mellitus
Sites: Buenos Aires, Argentina; Caba, Argentina; Capital Federal, Argentina · 95 sites in all
- Exenatide Versus Glimepiride in Patients With Type 2 DiabetesPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00359762 · 1,029 participants · Start Sep 2006 · Primary completion Mar 2011
Drug: exenatide; glimepiride · For: Type 2 Diabetes Mellitus
Sites: Graz, Austria; Innsbruck, Austria; Salzburg, Austria · 114 sites in all
- A Study in Participants With Type 2 Diabetes MellitusPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01064687 · 978 participants · Start Feb 2010 · Primary completion Nov 2011
Drug: LY2189265; Exenatide and 3 more · For: Diabetes Mellitus, Type 2
Sites: Goodyear, Arizona; Phoenix, Arizona; Cathedral City, California · 89 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased15,472
- weight decreased12,126
- nausea12,042
- decreased appetite5,643
- blood glucose decreased5,516
- vomiting4,346
- diarrhoea2,742
- dizziness2,674
- drug ineffective2,251
- headache2,087
- injection site pain2,023
- pancreatitis2,011
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1,970 |
| 2006 | 12,666 |
| 2007 | 12,432 |
| 2008 | 7,681 |
| 2009 | 2,461 |
| 2010 | 1,753 |
| 2011 | 1,820 |
| 2012 | 996 |
| 2013 | 1,460 |
| 2014 | 1,912 |
| 2015 | 2,516 |
| 2016 | 1,149 |
| 2017 | 892 |
| 2018 | 771 |
| 2019 | 642 |
| 2020 | 340 |
| 2021 | 274 |
| 2022 | 197 |
| 2023 | 127 |
| 2024 | 169 |
| 2025 | 75 |
| 2026 | 17 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Byetta (Exenatide)
2024 spending
$15.9M
Beneficiaries
3,043
11,712 claims
Per beneficiary
$5,218
$459.82 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $47,676,632 |
| 2021 | $37,988,662 |
| 2022 | $27,500,961 |
| 2023 | $20,645,626 |
| 2024 | $15,877,480 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes.
Johansen NJ, Dejgaard TF, Lund A, et al. · Diabetes Obes Metab 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
Salehi P, Hsu I, Azen CG, et al. · Pediatr Obes 2017 · Clinical Trial
- Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.
Johansen NJ, Dejgaard TF, Lund A, et al. · Lancet Diabetes Endocrinol 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
Yang J, Xiao W, Guo L, et al. · Acta Diabetol 2020 · Multicenter Study, Randomized Controlled Trial
- [Exenatide stimulated solute-free water excretion by human kidney].
Shakhmatova EI, Shutskaia ZhV, Vladimirova ME, et al. · Ross Fiziol Zh Im I M Sechenova 2012 · Clinical Trial, Research Support, Non-U.S. Gov't
- Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial.
Johansen NJ, Dejgaard TF, Lund A, et al. · Diabetes Obes Metab 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.